Erik Johan Frostegård
Direktor/Vorstandsmitglied bei ANNEXIN PHARMACEUTICALS AB
Profil
Erik Johan Frostegård is the founder of Athera Biotechnologies AB, which was founded in 2002.
He held the title of Director at Athera Biotechnologies AB.
Currently, Dr. Frostegård holds the position of Director at Annexin Pharmaceuticals AB since 2016.
He is also the Head of the Immunology & Chronic Disease Department at Karolinska Institutet and a Senior Consultant at Karolinska University Hospital.
Aktive Positionen von Erik Johan Frostegård
Unternehmen | Position | Beginn |
---|---|---|
ANNEXIN PHARMACEUTICALS AB | Direktor/Vorstandsmitglied | 01.01.2016 |
Karolinska Institutet | Corporate Officer/Principal | - |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Erik Johan Frostegård
Unternehmen | Position | Ende |
---|---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ANNEXIN PHARMACEUTICALS AB | Health Technology |
Private Unternehmen | 2 |
---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital. | Health Services |